Metacrine is a clinical-stage biopharmaceutical company developing targeted therapies for gastrointestinal and liver diseases, focusing on the modulation of nuclear receptors to improve patient outcomes. With over 3 million individuals in the U.S. affected by inflammatory bowel disease (IBD), Metacrine aims to provide effective treatment options that address unmet medical needs in this patient population.
Funding
Funding not disclosed
Founders
Product
Problem
Inflammatory bowel disease (IBD) affects millions, causing significant gastrointestinal distress and impacting quality of life. Current treatment options may not be effective for all patients, leaving unmet medical needs in managing these chronic conditions.
Solution
Metacrine is a biopharmaceutical company focused on developing targeted therapies for gastrointestinal and liver diseases. The company pioneers differentiated therapies for patients with GI and liver diseases. Metacrine's approach involves modulating nuclear receptors to improve patient outcomes in IBD and other related conditions. Their clinical-stage programs aim to provide effective treatment options that address unmet medical needs in this patient population.
Target Audience
The primary target audience includes individuals suffering from inflammatory bowel disease (IBD) and other gastrointestinal and liver diseases, as well as healthcare providers specializing in these conditions.
Features
- Focus on therapies for gastrointestinal (GI) and liver diseases
- Modulation of nuclear receptors for targeted treatment
- Clinical-stage development programs